Clinical Trial Update: A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ibandronate (Bondronat) in participants with malignant bone disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Bone Metastasis

Drugs mentioned

• Bondronat (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pain; Bone Neoplasms; Neoplasm Metastasis | Phase 3 | Status: COMPLETED